Radionuclide reporter gene imaging for cardiac gene therapy

Article

Abstract

Introduction

In the field of cardiac gene therapy, angiogenic gene therapy has been most extensively investigated. The first clinical trial of cardiac angiogenic gene therapy was reported in 1998, and at the peak, more than 20 clinical trial protocols were under evaluation. However, most trials have ceased owing to the lack of decisive proof of therapeutic effects and the potential risks of viral vectors. In order to further advance cardiac angiogenic gene therapy, remaining open issues need to be resolved: there needs to be improvement of gene transfer methods, regulation of gene expression, development of much safer vectors and optimisation of therapeutic genes. For these purposes, imaging of gene expression in living organisms is of great importance. In radionuclide reporter gene imaging, “reporter genes” transferred into cell nuclei encode for a protein that retains a complementary “reporter probe” of a positron or single-photon emitter; thus expression of the reporter genes can be imaged with positron emission tomography or single-photon emission computed tomography. Accordingly, in the setting of gene therapy, the location, magnitude and duration of the therapeutic gene co-expression with the reporter genes can be monitored non-invasively. In the near future, gene therapy may evolve into combination therapy with stem/progenitor cell transplantation, so-called cell-based gene therapy or gene-modified cell therapy.

Conclusion

Radionuclide reporter gene imaging is now expected to contribute in providing evidence on the usefulness of this novel therapeutic approach, as well as in investigating the molecular mechanisms underlying neovascularisation and safety issues relevant to further progress in conventional gene therapy.

Keywords

Positron emission tomography Single-photon emission computed tomography Reporter gene Gene therapy Myocardium 

References

  1. 1.
    Gambhir SS, Barrio JR, Herschman HR, Phelps ME. Imaging gene expression: principles and assays. J Nucl Cardiol 1999;6:219–33.PubMedCrossRefGoogle Scholar
  2. 2.
    Blasberg RG, Tjuvajev JG. Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Q J Nucl Med 1999;43:163–9.PubMedGoogle Scholar
  3. 3.
    Hajjar RJ, del Monte F, Matsui T, Rosenzweig A. Prospects for gene therapy for heart failure. Circ Res 2000;86:616–21.PubMedGoogle Scholar
  4. 4.
    Kibbe MR, Billiar TR, Tzeng E. Gene therapy for restenosis. Circ Res 2000;86:829–33.PubMedGoogle Scholar
  5. 5.
    Donahue JK, Kikuchi K, Sasano T. Gene therapy for cardiac arrhythmias. Trends Cardiovasc Med 2005;15:219–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Lee JS, Feldman AM. Gene therapy for therapeutic myocardial angiogenesis: a promising synthesis of two emerging technologies. Nat Med 1998;4:739–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000;355:213–22.PubMedCrossRefGoogle Scholar
  8. 8.
    Isner JM. Myocardial gene therapy. Nature 2002;415:234–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Freedman SB, Isner JM. Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol 2001;33:379–93.PubMedCrossRefGoogle Scholar
  10. 10.
    Hammond HK, McKirnan MD. Angiogenic gene therapy for heart disease: a review of animal studies and clinical trials. Cardiovasc Res 2001;49:561–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800–4.PubMedGoogle Scholar
  12. 12.
    Yla-Herttuala S, Markkanen JE, Rissanen TT. Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials. Trends Cardiovasc Med 2004;14:295–300.PubMedCrossRefGoogle Scholar
  13. 13.
    Brewster LP, Brey EM, Greisler HP. Cardiovascular gene delivery: The good road is awaiting. Adv Drug Deliv Rev 2006;58:604–29.PubMedCrossRefGoogle Scholar
  14. 14.
    NIH resources page. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov/. Accessed January 31, 2007.
  15. 15.
    Inubushi M, Tamaki N. PET reporter gene imaging in myocardium: for monitoring of angiogenic gene therapy in ischemic heart disease. J Card Surg 2005;20:S20–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Shepherd FA, Sridhar SS. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 2003;41(Suppl 1):S63–72, Aug.PubMedCrossRefGoogle Scholar
  17. 17.
    Sridhar SS, Shepherd FA. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003;42(Suppl 1):S81–91.PubMedCrossRefGoogle Scholar
  18. 18.
    Kleiman NS, Patel NC, Allen KB, et al. Evolving revascularization approaches for myocardial ischemia. Am J Cardiol 2003;92:9N–17N.PubMedCrossRefGoogle Scholar
  19. 19.
    Rubanyi GM. The future of human gene therapy. Mol Aspects Med 2001;22:113–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost 1997;78:672–7.PubMedGoogle Scholar
  21. 21.
    Stolberg SG. The biotech death of Jesse Gelsinger. NY Times Mag 1999. Nov. 28, 136–50.Google Scholar
  22. 22.
    Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148–58.PubMedCrossRefGoogle Scholar
  23. 23.
    Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002;110:521–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Tsurumi Y, Takeshita S, Chen D, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996;94:3281–90.PubMedGoogle Scholar
  27. 27.
    Laitinen M, Pakkanen T, Luoma J, et al. Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of plasmid-liposome complexes, retroviruses, pseudotyped retroviruses and adenoviruses. Hum Gene Ther 1997;9:1645–50.CrossRefGoogle Scholar
  28. 28.
    Taniyama Y, Tachibana K, Hiraoka K, et al. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther 2002;9:372–80.PubMedCrossRefGoogle Scholar
  29. 29.
    Hartikka J, Sukhu L, Buchner C, et al. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. Mol Ther 2001;4:407–15.PubMedCrossRefGoogle Scholar
  30. 30.
    Gardlik R, Palffy R, Hodosy J, Lukacs J, Turna J, Celec P. Vectors and delivery systems in gene therapy. Med Sci Monit 2005;11:RA110–21.PubMedGoogle Scholar
  31. 31.
    Avril N, Bengel FM. Defining the success of cardiac gene therapy: how can nuclear imaging contribute? Eur J Nucl Med Mol Imaging 2003;30:757–71.PubMedCrossRefGoogle Scholar
  32. 32.
    Wu JC, Tseng JR, Gambhir SS. Molecular imaging of cardiovascular gene products. J Nucl Cardiol 2004;11:491–505.PubMedCrossRefGoogle Scholar
  33. 33.
    Serganova I, Blasberg R. Reporter gene imaging: potential impact on therapy. Nucl Med Biol 2005;32:763–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Inubushi M, Wu JC, Gambhir SS, et al. Positron-emission tomography reporter gene expression imaging in rat myocardium. Circulation 2003;107:326–32.PubMedCrossRefGoogle Scholar
  35. 35.
    Tjuvajev JG, Doubrovin M, Akhurst T, et al. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med 2002;43:1072–83.PubMedGoogle Scholar
  36. 36.
    Min JJ, Iyer M, Gambhir SS. Comparison of [18F]FHBG and [14C]FIAU for imaging of HSV1-tk reporter gene expression: adenoviral infection vs stable transfection. Eur J Nucl Med Mol Imaging 2003;30:1547–60.PubMedCrossRefGoogle Scholar
  37. 37.
    Miyagawa M, Beyer M, Wagner B, et al. Cardiac reporter gene imaging using the human sodium/iodide symporter gene. Cardiovasc Res 2005;65:195–202.PubMedCrossRefGoogle Scholar
  38. 38.
    Yau TM, Kim C, Li G, Zhang Y, Weisel RD, Li RK. Maximizing ventricular function with multimodal cell-based gene therapy. Circulation 2005;112:I123–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Iwaguro H, Asahara T. Endothelial progenitor cell culture and gene transfer. Methods Mol Med 2005;112:239–47.PubMedGoogle Scholar
  40. 40.
    Iwaguro H, Yamaguchi J, Kalka C, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002;105:732–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Department of Molecular ImagingHokkaido University Graduate School of MedicineSapporoJapan
  2. 2.Department of Nuclear MedicineHokkaido University Graduate School of MedicineSapporoJapan

Personalised recommendations